Description

(1-Methyl-2,4-Dioxo-1,3-Diaza-Spiro[4.5]Dec-3-Yl)-Acetic Acid is a high-purity, advanced pharmaceutical intermediate characterized by its unique spirocyclic hydantoin-acetic acid structure. This compound is of significant commercial value for its role as a critical building block in the synthesis of novel active pharmaceutical ingredients (APIs), particularly in therapeutic areas requiring complex molecular architectures. It is primarily sought by research institutions and manufacturers in the global pharmaceutical and biotechnology sectors for developing next-generation drug candidates.

Application

• Pharmaceutical Intermediate: A key synthon for the research and development of new chemical entities (NCEs) and active pharmaceutical ingredients (APIs).
• Protease Inhibitor Synthesis: Serves as a core scaffold in the design and production of protease inhibitors for antiviral and anticancer therapies.
• Neurological Drug Development: Used in constructing molecules targeting neurological disorders due to the bioactivity of the hydantoin moiety.
• Peptidomimetics Research: Acts as a constrained, non-natural amino acid analog in the creation of peptidomimetic compounds to enhance drug stability and bioavailability.
• Chemical Biology & Medicinal Chemistry: Employed in library synthesis for high-throughput screening and structure-activity relationship (SAR) studies.
• Custom Synthesis & Contract Manufacturing: Supplied to CDMOs (Contract Development and Manufacturing Organizations) for custom synthesis projects under cGMP guidelines.

Basic Information

Product Name	(1-Methyl-2,4-Dioxo-1,3-Diaza-Spiro[4.5]Dec-3-Yl)-Acetic Acid
CAS No.	852400-33-0
Molecular Formula	C11H16N2O4
Molecular Weight	240.26 g/mol
Synonyms	1-Methyl-2,4-dioxo-1,3-diaza-spiro[4.5]decane-3-acetic acid; 3-Carboxymethyl-1-methylspirohydantoin; Spiro[4.5]decane-3-acetic acid, 1-methyl-2,4-dioxo-1,3-diaza-; 1-Methyl-3-(carboxymethyl)spirohydantoin; 1-Methylspirohydantoin-3-acetic acid; (1-Methyl-2,4-dioxo-1,3-diaza-spiro[4.5]dec-3-yl)acetic acid; MDDSA
EINECS	Contact for details

Quality Control

Our (1-Methyl-2,4-Dioxo-1,3-Diaza-Spiro[4.5]Dec-3-Yl)-Acetic Acid is manufactured under strict quality management systems. We provide material that meets exacting standards for pharmaceutical R&D and scale-up. Certificates of Analysis (COA) are supplied with each batch, detailing purity, identity, and impurity profiles as confirmed by HPLC, NMR, and MS. Our quality commitment ensures reliable supply and batch-to-batch consistency critical for your development timelines.

Storage

Preserve in a tightly closed container, protected from light. Store in a cool, dry, and well-ventilated area at a controlled room temperature (15-25°C). The product may be hygroscopic (moisture-sensitive); keep the container tightly sealed in a dry environment.

Specification

Item	Specification
Appearance	White to off-white crystalline powder
Identification (IR)	Conforms to structure
Identification (HPLC)	Retention time matches reference standard
Assay (HPLC)	≥ 98.0%
Related Substances (HPLC)	Total impurities ≤ 2.0% Any single impurity ≤ 1.0%
Water Content (KF)	≤ 0.5%
Residue on Ignition	≤ 0.1%

Note: Specifications can be tailored. Please contact us for the detailed technical data sheet of a specific grade.